This article refers to 'European Society of Cardiology Core Curruculum for cardio-oncology' by T. López-Fernández et al., published in this issue on pages 754-771.The landscape of cancer survivorship has been significantly shaped by the success of modern anticancer treatments, leading to a growing number of individuals triumphing over cancer. According to World Health Organization, in 2022, there were 20 million new cases of cancer and 53.5 million individuals were alive 5 years after a cancer diagnosis. 1 In the United States (US) alone, the number of cancer survivors has increased from ∼3 million in the 1970s to over 18 million in 2022. 2 However, this victory is not without challenges. The ever-increasing number of cancer therapeutics across the spectrum of chemotherapy, targeted therapies, immunotherapies and radiation therapy have been associated with a variety of cardiovascular (CV) toxicities ranging from cardiomyopathy and heart failure to arrhythmias, cardiometabolic disorders, hypertension, vascular disease and myocarditis. 3 Notably, CV disease and cancer therapy-related CV toxicity (CTR-CVT) is the second leading cause of mortality among cancer survivors. 4 Recognition of this critical intersection between oncology and cardiology has created a need to effectively train the international workforce for the growing cardio-oncology patient population.Specialized cardio-oncology clinics and inpatient services have rapidly emerged as essential to addressing the unique CV concerns of individuals requiring treatment for cancer and for cancer survivors, especially in Europe 5 and the US. 6 Although there are at least 134 cardio-oncology programmes from 28 countries globally registered with the International Cardio-Oncology Society (IC-OS), 7 this is likely an underestimate as many healthcare systems and physician groups are providing cardio-oncology services that are not officially recognized.The scope of cardio-oncologists has also broadened from the initial need of managing CTR-CVT to a pivotal role which nowThe opinions expressed in this article are not necessarily those of the Editors of the European Journal of Heart Failure or of the European Society of Cardiology.